Tango Therapeutics Inc (TNGX)

NASD · Healthcare · Biotechnology · USA

Tango Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Tango Therapeutics develops targeted oncology medicines by identifying novel targets and designing small molecules tailored to cancer cells with specific genetic alterations. The company is advancing clinical development of two PRMT5 inhibitors: vopimetostat for non-CNS tumors both alone and paired with RAS inhibitors, and TNG456, a brain-penetrant variant for CNS cancers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Tango Therapeutics Inc stock.

Our verdict on TNGX

Not valued: We cannot value this company yet.

ETFs with the most weight in TNGX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than TNGX in Biotechnology

129 more in this industry show a wider margin of safety.

Is TNGX undervalued or overvalued?

We do not publish a verdict on TNGX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of TNGX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.